Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Fibrosis is the result of an overly abundant deposition of extracellular matrix (ECM) due to the fact of repetitive tissue injuries and/or dysregulation of the repair process. Fibrogenesis is a pathogenetic phenomenon which is involved in different chronic human diseases, accounting for a high burden of morbidity and mortality. Despite being triggered by different causative factors, fibrogenesis follows common pathways, the knowledge of which is, however, still unsatisfactory. This represents a significant limit for the development of effective antifibrotic drugs. In the present paper, we aimed to review the current evidence regarding the potential role played in fibrogenesis by growth arrest-specific 6 (Gas6) and its receptors Tyro3 protein tyrosine kinase (Tyro3), Axl receptor tyrosine kinase (Axl), and Mer tyrosine kinase protooncogene (MerTK) (TAM). Moreover, we aimed to review data about the pathogenetic role of this system in the development of different human diseases characterized by fibrosis. Finally, we aimed to explore the potential implications of these findings in diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Different triggers can lead to the development of progressive fibrotic diseases, such as infections, exposure to toxins/irritants/smoke, chronic autoimmune reactions, and ischemia [2].”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“The development of diffuse fibrosis impairs the physiological activities of involved tissues and organs, representing a common pathogenetic element of many chronic inflammatory diseases, such as liver cirrhosis, kidney disease, interstitial lung disease, autoimmune diseases, and heart failure [3].”
BackgroundA gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Thorp, E., Vaisar, T., Subramanian, M., Mautner, L., Blobel, C., & Tabas, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.263020 · Cited by 298 · cited 1×
“All three types of TAM receptors can be found in human plasma in their soluble (sTyro3, sAxl e, sMer) forms as a result of membrane receptor cleavage mediated by two metalloproteases (ADAM 10 and ADAM 17); although a definite function of soluble receptors has not yet been defined, a decoy activity has been proposed [1…”
BackgroundBernsmeier, C., Pop, O. T., Singanayagam, A., Triantafyllou, E., Patel, V. C., Weston, C. J., Curbishley, S., Sadiq, F., Vergis, N., Khamri, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.045 · Cited by 287 · cited 1×
“When cultured and stimulated with lipopolysaccharide, MerTK-expressing monocytes show a reduced production of proinflammatory cytokines, reversed by the use of a MerTK inhibitor [32].”
BackgroundMerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
Triantafyllou, E., Pop, O. T., Possamai, L. A., Wilhelm, A., Liaskou, E., Singanayagam, A., Bernsmeier, C., Khamri, W., Petts, G., Dargue, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313615 · Cited by 226 · cited 1×
“Consistently, MerTK −/− KO mice exhibit persistent liver injury and inflammation after acetaminophen (APAP)-induced acute liver damage [33].”
BackgroundAit-Oufella, H., Pouresmail, V., Simon, T., Blanc-Brude, O., Kinugawa, K., Merval, R., Offenstadt, G., Lesèche, G., Cohen, P. L., Tedgui, A., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.169078 · Cited by 187 · cited 1×
“Moreover, cultured splenocytes isolated from MerTK −/− KO mice showed enhanced production of pro-inflammatory cytokines and MerTK deficiency led to accelerated atherosclerosis [48].”
Background
Cited by
The clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
“Interestingly, mouse models of liver injury that are not related to NASH or that are too far separated from human NASH may not capture the directionality of the human genetic data for NASH (Bellan et al., 2019), where variants that lower MerTK expression are associated with protection against NASH fibrosis (Petta et a…”
BackgroundMladěnka, P., Macáková, K., Kujovská Krčmová, L., Javorská, L., Mrštná, K., Carazo, A., Protti, M., Remião, F., Nováková, L., & collaborators, T. O. R. A. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuab061 · Cited by 262
Henlon, Y., Panir, K., McIntyre, I., Hogg, C., Dhami, P., Cuff, A. O., Senior, A., Moolchandani-Adwani, N., Courtois, E. T., Horne, A. W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405474121 · Cited by 56
“In other systems, this pathway has been intimately linked with the process of fibrosis, including in lung and liver fibrosis ( 38 ).”
BackgroundA+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis
Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., Ou, Y., Liang, X., Zhang, H., Li, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.016 · Cited by 39
Metadata
- Authors
- Bellan, M., Cittone, M. G., Tonello, S., Rigamonti, C., Castello, L. M., Gavelli, F., Pirisi, M., & Sainaghi, P. P.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-10-12
- Volume
- 20
- Issue
- 20
- Pages
- 5070
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2979361795
- Cited by
- 85
- References
- 11
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.